1. Switzerland Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Lonza Group AG

Lonza Group AG

663.60
EUR
-7.40
(-1.10%)
Jan 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
63.91
64.86
67.4
72.85
67
74.48
56.77
60.59
72.84
83.83
91.23
76.99
93.27
- -
Basic EPS, GAAP
1.55
4.22
4.91
5.31
10.42
7.51
8.7
11.68
39.65
16.37
8.88
8.94
-3.93
- -
Free Cash Flow per Basic Share
5.55
5.4
8.45
6.81
5.75
6.81
2.42
2.11
-1.67
-11.48
-3.99
-2.01
-3.1
- -
Dividend per Share
2
2
2.32
2.31
2.36
2.77
2.78
2.77
3.03
3.07
3.57
4.05
4.03
- -
Book Value per Share
37.89
37.93
37.83
40.39
82.61
83.75
87.42
91.74
131.42
142.66
131.07
132.06
113.29
116.26
Tangible Book Value per Share
4.94
2.19
3.26
0.82
-21.15
-11.34
-3.1
14.85
58.09
74.08
65.34
56.02
80.54
83.63
Basic Weighted Avg Shares
56
56
56
57
68
74
74
74
74
74
74
71
70
70
Sales/Revenue/Turnover
3,584
3,640
3,803
4,132
4,548
5,542
4,207
4,508
5,409
6,223
6,717
5,480
6,531
- -
Operating Margin (%)
7.06
11.62
11.39
12.92
14.31
16.37
20.2
20.67
15.29
21.81
13
16.04
20.79
- -
Depreciation Expense
309
299
300
307
411
526
544
526
522
596
621
647
813
- -
Net Income, GAAP
87
237
277
301
707
559
645
869
2,944
1,215
654
636
-275
- -
Effective Tax Rate (%)
17.14
15.05
18.77
19.3
- -
18.34
9.87
8.84
10.92
15.88
17.09
14.97
17.44
- -
Profit Margin (%)
2.43
6.51
7.28
7.28
15.55
10.09
15.33
19.28
54.43
19.52
9.74
11.61
-4.21
- -
Working Capital
655
323
268
433
560
1,134
365
1,704
3,585
2,637
2,139
1,861
3,209
2,764
LT Debt
2,245
1,693
1,414
1,571
3,730
3,621
2,985
2,994
2,530
1,855
2,905
4,608
4,197
3,393
Total Equity
2,126
2,130
2,135
2,302
6,181
6,290
6,565
6,884
9,823
10,665
9,512
9,388
7,966
8,152
Return on Invested Capital (%)
4.32
7.89
8.11
9.34
- -
6.44
7.08
7.69
6.44
9.96
5.6
5.65
7.53
- -
Return on Capital (%)
3.71
6.73
8.12
8.78
- -
6.11
6.87
8.85
25.87
9.8
5.64
5.55
-1.04
- -
Return on Common Equity (%)
4.11
11.14
12.99
13.57
16.76
9.05
10.15
13.06
35.54
11.94
6.52
6.77
-3.19
- -

Capital Structure

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
415
343
774
LT Borrowings
4,199
3,876
3,393
LT Finance Leases
- -
321
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
70
70
70
Market Capitalization
- -
- -
- -

Working Capital

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
4,589
6,834
6,936
Cash, Cash Equivalents & STI
907
719
487
Accounts Receivable, Net
1,805
1,062
1,920
Inventories
1,843
1,680
1,880
Total Current Liabilities
3,151
3,625
4,172
Payables & Accruals
- -
- -
- -
ST Debt
415
343
774
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.13%
4.8%
-15.15%
Free Cash Flow
27.8%
68.6%
51.75%
Net Income, GAAP
16.06%
-2.42%
-143.24%
Sales/Revenue/Turnover
6.74%
8.75%
19.18%
Total Cash Common Dividend
- -
6.67%
-2.08%

Semi-annual Revenue

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
5,480
2025
- -
- -
6,531
2026
- -
- -
- -

Semi-annual Earnings Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
8.94
2025
- -
- -
-3.93
2026
- -
- -
- -

Semi-annual Dividends Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
4.05
2025
- -
- -
4.03
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Wolfgang Wienand
Full Time Employees
16,866
Sector
Health technology
Industry
Biotechnology
Address
Muenchensteinerstrasse 38 Basel BS Switzerland 4002
IPO Date
Apr 3, 2002
Website
lonza.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Lonza Group AG is a leading contract development and manufacturing organization (CDMO) in the biopharmaceutical industry, providing end-to-end solutions for biologics, small molecules, cell and gene therapies, and microbial products. The company offers services including cell line development, process development, analytical services, clinical and commercial manufacturing, and formulation technologies such as encapsulated cell therapies and lipid nanoparticles; its key product categories encompass monoclonal antibodies, bispecifics, mRNA vaccines, viral vectors, and biosimilars, supported by proprietary platforms like Cocoon for personalized medicines and Lysogenix for biocatalysis. Lonza operates globally across North America, Europe, Asia-Pacific, and Latin America, serving pharmaceutical, biotech, and academic customers with facilities in Switzerland, the United States, Singapore, and China. Founded in 1897 and headquartered in Basel, Switzerland (ticker: LONN.SW), Lonza focuses on accelerating drug development and commercialization through its expertise in bioconjugates, antibody-drug conjugates, and advanced therapy medicinal products. In the past two years, Lonza has expanded through strategic moves including the 2024 acquisition of In Vitro Technologies to bolster Australian operations, a multi-year partnership with NVIDIA in 2025 to integrate AI into bioprocessing for faster drug discovery, the launch of a new bioconjugates facility in Boston in 2024, and a CHF 1 billion investment announced in 2025 for cell and gene therapy capacity in the US and Europe to meet surging demand in personalized medicines.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Lonza: Strong H1 Execution, Higher Guidance Means Higher Upside

  • seekingalpha.com

    Lonza Group AG (LZAGY) Q1 2026 Earnings Call Transcript